Tamtam Try Tamtam free
Gustave Roussy logo

Gustave Roussy account plan

Cancer treatment and research

At a glance

Gustave Roussy is a French comprehensive cancer centre in Villejuif with a 633 M€ budget, 4,000 employees and 24,000 new patients in 2025.

Gustave Roussy is a French comprehensive cancer centre (centre de lutte contre le cancer) in Villejuif, Val-de-Marne, combining care, research, education and technology transfer, with philanthropy run through the Gustave Roussy Fondation. It presents itself as first in France and in Europe by number of patients included in clinical trials. In 2025 it ran a 633 M€ budget (expenses of 633 M€ against income of 632 M€, two-thirds from hospital care), with 4,000 employees including 1,400 researchers and research staff, and 600 beds and places. It saw 24,000 new patients, 354,000 medical consultations and 144,000 stays. Its stated goal is to cure 80% of cancers by 2040.

Business units

Strategic priorities

Cure 80% of cancers by 2040
The Projet d'établissement 2026-2030 keeps this goal and is built on four axes: individualised care pathways, high-impact research, resources matching ambitions, and digital and AI transformation.
High-impact research
Reach 60 research teams by 2030 including 20 ERC-funded, include 1,000 patients in the DITEP early-trials department in 2030, lead at least two practice-changing trials a year and create an institute for cancers of young people.
Digital and AI transformation
The information-systems budget doubled in two years; SI foundations are rebuilt in 2026, with DxCare, Chimio-Pharma and Doctolib in 2026, a move to Care4U in 2028-2030 and the GOLDEN health-data warehouse.
Double philanthropy
Raise philanthropic collection to an annual target of 80 M€ by 2030, with 80% of collection dematerialised through a new AI-supported CRM.
Financial balance
Keep a minimum self-financing capacity of 30 M€ a year on average over 2026-2030, with multi-year budget scenarios.
Early detection and individualised pathways
Extend rapid diagnosis to all pathologies, scale up Interception and focus on key stages such as prevention, screening and initial treatment.

Investments and deals

Cancer campus plan
A 480 M€ investment plan over five years for what the report calls the largest cancer campus in Europe, with three new buildings in five years.
Research building
A 33,000 m² building costing 190 M€ to host 60 research teams and 12 technology platforms, with delivery planned end 2028 / early 2029.
Education-office-parking and ambulatory buildings
An education-office-parking building due in 2028 and a new ambulatory building for rapid diagnosis and Interception by the end of the plan.
Equipment and energy
New heavy imaging and radiotherapy equipment and operating-theatre renovation are planned; 1.2 M€ invested in the heat network cut gas consumption by 42% versus 2024.

Challenges and risks

Scarcer resources
The plan is set in a context of accelerating innovation and scarcer resources; the Director General says research costs more and more and national cancer strategy funding remains relatively little.
Talent competition in Île-de-France
Strong tension on health professions and competition for nurses, radiographers and IT/data talent; more than 100 nurses were recruited in 2025.
Thin financial balance
2025 expenses of 633 M€ slightly exceeded income of 632 M€ while the institution invests heavily in its campus.
Health sovereignty
Barlesi warns that Europe and France risk dependence on the US and China if they cannot develop and manufacture some of their own drugs.
AI ethics and validation
AI use in care and research requires human validation and ethics safeguards.

What leadership says

“What we want with this campus is to industrialise serendipity”

Pr Fabrice Barlesi, Director General · Kadans Oncology Summit, Paris, 4 June 2026 (Pharmaceutical Technology)

“I believe that Europe and France are caught in the middle of two giants”

Pr Fabrice Barlesi, Director General · Kadans Oncology Summit, Paris, 4 June 2026 (Pharmaceutical Technology)

“If we cannot develop at least some of the drugs we will need in the future, we risk becoming dependent on these two powers. We need to protect ourselves.”

Pr Fabrice Barlesi, Director General · Kadans Oncology Summit, Paris, 4 June 2026 (Pharmaceutical Technology)

Where a supplier can help

Clinical IT and data platforms
Tied to the digital and AI priority: the DxCare-to-Care4U migration, the GOLDEN data warehouse and AI in record summaries and coding open room for software, integration and data suppliers.
Fundraising CRM and donor engagement
Tied to the goal of 80 M€ of annual philanthropy by 2030 with an AI-supported CRM and 80% dematerialised collection.
Construction and campus equipment
Tied to the 480 M€ campus plan: laboratory fit-out, heavy imaging, radiotherapy and building services for the research and ambulatory buildings.
Recruitment and retention
Tied to the talent challenge: recruitment, training and employer-brand services for nurses, radiographers and IT/data profiles in Île-de-France.
Biotech and industry partnerships
Tied to the sovereignty challenge and technology transfer: pharma, investors and manufacturing partners that help turn Gustave Roussy discoveries into therapies made in France.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Gustave Roussy?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Gustave Roussy

What is Gustave Roussy?

Gustave Roussy is a French comprehensive cancer centre in Villejuif that combines patient care, research, education and technology transfer. It presents itself as first in France and Europe by number of patients included in clinical trials.

How big is Gustave Roussy?

In 2025 it had a 633 M€ budget, 4,000 employees, 600 beds and places, 24,000 new patients and 354,000 medical consultations.

What is Gustave Roussy's strategy?

Its Projet d'établissement 2026-2030 aims to cure 80% of cancers by 2040 through individualised care pathways, high-impact research, secured resources and digital and AI transformation.

Who leads Gustave Roussy?

Pr Fabrice Barlesi is Director General; Pr Fabrice André is Director of Research and Dr Valérie Lapierre is CME President.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)